Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. PYX-201, the company’s lead ...

Looking for information on Pattaya Airport, Pattaya, Thailand? Know about Pattaya Airport in detail. Find out the location of Pattaya Airport on Thailand map and also find out airports near to Pattaya ...

PYX-201, the Company’s lead clinical drug candidate, is a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets ...

- PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

(RTTNews) - Pyxis Oncology (PYXS), a clinical-stage biopharmaceutical company, announced on Wednesday that its lead drug candidate, PYX-201, has shown promising results in an ongoing Phase 1 ...

Beyond head and neck squamous cell carcinoma (HNSCC), in which PYX-201 found the most success, the drug’s activity appears “modest” at best in other tumor types, the William Blair team ...

In this ongoing open-label, multicenter, dose-escalation Phase 1 trial of PYX-201, 80 patients have been enrolled and dosed across multiple solid tumor types to receive doses of PYX-201 ranging ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in ...

Pope Francis has published a letter addressed especially to priests in formation to promote the renewal of the study of Church history, emphasizing its importance in better interpreting reality ...